Pharmacological characterization of a novel, potent, selective, and orally active fatty acid amide hydrolase inhibitor, PKM‐833 [(R)‐N‐(pyridazin‐3‐yl)‐4‐(7‐(trifluoromethyl)chroman‐4‐yl)piperazine‐1‐carboxamide] in rats: Potential for the treatment of inflammatory pain

Abstract Recently, we identified a novel fatty acid amide hydrolase (FAAH) inhibitor, PKM‐833 [(R)‐N‐(pyridazin‐3‐yl)‐4‐(7‐(trifluoromethyl)chroman‐4‐yl)piperazine‐1‐carboxamide]. The aim of the present study is to characterize the pharmacological profile of PKM‐833 in vitro and in vivo. PKM‐833 sho...

Full description

Bibliographic Details
Main Authors: Toshiya Endo, Takashi Takeuchi, Shunsuke Maehara
Format: Article
Language:English
Published: Wiley 2020-04-01
Series:Pharmacology Research & Perspectives
Subjects:
Online Access:https://doi.org/10.1002/prp2.569
id doaj-a3750ea67c904ecc8b30bc829e60e18e
record_format Article
spelling doaj-a3750ea67c904ecc8b30bc829e60e18e2021-05-02T16:49:56ZengWileyPharmacology Research & Perspectives2052-17072020-04-0182n/an/a10.1002/prp2.569Pharmacological characterization of a novel, potent, selective, and orally active fatty acid amide hydrolase inhibitor, PKM‐833 [(R)‐N‐(pyridazin‐3‐yl)‐4‐(7‐(trifluoromethyl)chroman‐4‐yl)piperazine‐1‐carboxamide] in rats: Potential for the treatment of inflammatory painToshiya Endo0Takashi Takeuchi1Shunsuke Maehara2Biology Laboratory Discovery Research Mochida Pharmaceutical Co., Ltd. Gotemba Shizuoka JapanBiology Laboratory Discovery Research Mochida Pharmaceutical Co., Ltd. Gotemba Shizuoka JapanBiology Laboratory Discovery Research Mochida Pharmaceutical Co., Ltd. Gotemba Shizuoka JapanAbstract Recently, we identified a novel fatty acid amide hydrolase (FAAH) inhibitor, PKM‐833 [(R)‐N‐(pyridazin‐3‐yl)‐4‐(7‐(trifluoromethyl)chroman‐4‐yl)piperazine‐1‐carboxamide]. The aim of the present study is to characterize the pharmacological profile of PKM‐833 in vitro and in vivo. PKM‐833 showed potent inhibitory activities against human and rat FAAH with IC50 values of 8.8 and 10 nmol/L, respectively, 200‐fold more selectivity against other 137 molecular targets, and irreversible mode of action. In pharmacokinetic and pharmacodynamic studies, PKM‐833 showed excellent brain penetration and good oral bioavailability, and elevated anandamide (AEA) concentrations in the rat brain. These data indicate that PKM‐833 is a potent, selective, orally active, and brain‐penetrable FAAH inhibitor. In behavioral studies using rat models, PKM‐833 significantly attenuated formalin‐induced pain responses (3 mg/kg) and improved mechanical allodynia in complete freund's adjuvant (CFA)‐induced inflammatory pain (0.3‐3 mg/kg). On the other hand, PKM‐833 did not show the analgesic effects against mechanical allodynia in chronic constriction injury (CCI)‐induced neuropathic pain up to 30 mg/kg. Regarding side effects, PKM‐833 had no significant effects on catalepsy and motor coordination up to 30 mg/kg. These results indicate that PKM‐833 is a useful pharmacological agent that can be used to investigate the role of FAAH and may have therapeutic potential for the treatment of inflammatory pain without undesirable side effects.https://doi.org/10.1002/prp2.569analgesiaanandamideendocannabinoidFAAHPKM‐833
collection DOAJ
language English
format Article
sources DOAJ
author Toshiya Endo
Takashi Takeuchi
Shunsuke Maehara
spellingShingle Toshiya Endo
Takashi Takeuchi
Shunsuke Maehara
Pharmacological characterization of a novel, potent, selective, and orally active fatty acid amide hydrolase inhibitor, PKM‐833 [(R)‐N‐(pyridazin‐3‐yl)‐4‐(7‐(trifluoromethyl)chroman‐4‐yl)piperazine‐1‐carboxamide] in rats: Potential for the treatment of inflammatory pain
Pharmacology Research & Perspectives
analgesia
anandamide
endocannabinoid
FAAH
PKM‐833
author_facet Toshiya Endo
Takashi Takeuchi
Shunsuke Maehara
author_sort Toshiya Endo
title Pharmacological characterization of a novel, potent, selective, and orally active fatty acid amide hydrolase inhibitor, PKM‐833 [(R)‐N‐(pyridazin‐3‐yl)‐4‐(7‐(trifluoromethyl)chroman‐4‐yl)piperazine‐1‐carboxamide] in rats: Potential for the treatment of inflammatory pain
title_short Pharmacological characterization of a novel, potent, selective, and orally active fatty acid amide hydrolase inhibitor, PKM‐833 [(R)‐N‐(pyridazin‐3‐yl)‐4‐(7‐(trifluoromethyl)chroman‐4‐yl)piperazine‐1‐carboxamide] in rats: Potential for the treatment of inflammatory pain
title_full Pharmacological characterization of a novel, potent, selective, and orally active fatty acid amide hydrolase inhibitor, PKM‐833 [(R)‐N‐(pyridazin‐3‐yl)‐4‐(7‐(trifluoromethyl)chroman‐4‐yl)piperazine‐1‐carboxamide] in rats: Potential for the treatment of inflammatory pain
title_fullStr Pharmacological characterization of a novel, potent, selective, and orally active fatty acid amide hydrolase inhibitor, PKM‐833 [(R)‐N‐(pyridazin‐3‐yl)‐4‐(7‐(trifluoromethyl)chroman‐4‐yl)piperazine‐1‐carboxamide] in rats: Potential for the treatment of inflammatory pain
title_full_unstemmed Pharmacological characterization of a novel, potent, selective, and orally active fatty acid amide hydrolase inhibitor, PKM‐833 [(R)‐N‐(pyridazin‐3‐yl)‐4‐(7‐(trifluoromethyl)chroman‐4‐yl)piperazine‐1‐carboxamide] in rats: Potential for the treatment of inflammatory pain
title_sort pharmacological characterization of a novel, potent, selective, and orally active fatty acid amide hydrolase inhibitor, pkm‐833 [(r)‐n‐(pyridazin‐3‐yl)‐4‐(7‐(trifluoromethyl)chroman‐4‐yl)piperazine‐1‐carboxamide] in rats: potential for the treatment of inflammatory pain
publisher Wiley
series Pharmacology Research & Perspectives
issn 2052-1707
publishDate 2020-04-01
description Abstract Recently, we identified a novel fatty acid amide hydrolase (FAAH) inhibitor, PKM‐833 [(R)‐N‐(pyridazin‐3‐yl)‐4‐(7‐(trifluoromethyl)chroman‐4‐yl)piperazine‐1‐carboxamide]. The aim of the present study is to characterize the pharmacological profile of PKM‐833 in vitro and in vivo. PKM‐833 showed potent inhibitory activities against human and rat FAAH with IC50 values of 8.8 and 10 nmol/L, respectively, 200‐fold more selectivity against other 137 molecular targets, and irreversible mode of action. In pharmacokinetic and pharmacodynamic studies, PKM‐833 showed excellent brain penetration and good oral bioavailability, and elevated anandamide (AEA) concentrations in the rat brain. These data indicate that PKM‐833 is a potent, selective, orally active, and brain‐penetrable FAAH inhibitor. In behavioral studies using rat models, PKM‐833 significantly attenuated formalin‐induced pain responses (3 mg/kg) and improved mechanical allodynia in complete freund's adjuvant (CFA)‐induced inflammatory pain (0.3‐3 mg/kg). On the other hand, PKM‐833 did not show the analgesic effects against mechanical allodynia in chronic constriction injury (CCI)‐induced neuropathic pain up to 30 mg/kg. Regarding side effects, PKM‐833 had no significant effects on catalepsy and motor coordination up to 30 mg/kg. These results indicate that PKM‐833 is a useful pharmacological agent that can be used to investigate the role of FAAH and may have therapeutic potential for the treatment of inflammatory pain without undesirable side effects.
topic analgesia
anandamide
endocannabinoid
FAAH
PKM‐833
url https://doi.org/10.1002/prp2.569
work_keys_str_mv AT toshiyaendo pharmacologicalcharacterizationofanovelpotentselectiveandorallyactivefattyacidamidehydrolaseinhibitorpkm833rnpyridazin3yl47trifluoromethylchroman4ylpiperazine1carboxamideinratspotentialforthetreatmentofinflammatorypain
AT takashitakeuchi pharmacologicalcharacterizationofanovelpotentselectiveandorallyactivefattyacidamidehydrolaseinhibitorpkm833rnpyridazin3yl47trifluoromethylchroman4ylpiperazine1carboxamideinratspotentialforthetreatmentofinflammatorypain
AT shunsukemaehara pharmacologicalcharacterizationofanovelpotentselectiveandorallyactivefattyacidamidehydrolaseinhibitorpkm833rnpyridazin3yl47trifluoromethylchroman4ylpiperazine1carboxamideinratspotentialforthetreatmentofinflammatorypain
_version_ 1721489863701692416